Srinivas Ganta, Amit Singh, Praveen Kulkarni, Amanda W Keeler, Aleksandr Piroyan, Rupa R Sawant, Niravkumar R Patel, Barbara Davis, Craig Ferris, Sara O'Neal, William Zamboni, Mansoor M Amiji, Timothy P Coleman
PURPOSE: Platinum-based therapies are the first line treatments for most types of cancer including ovarian cancer. However, their use is associated with dose-limiting toxicities and resistance. We report initial translational studies of a theranostic nanoemulsion loaded with a cisplatin derivative, myrisplatin and pro-apoptotic agent, C6-ceramide. METHODS: The surface of the nanoemulsion is annotated with an endothelial growth factor receptor (EGFR) binding peptide to improve targeting ability and gadolinium to provide diagnostic capability for image-guided therapy of EGFR overexpressing ovarian cancers...
August 2015: Pharmaceutical Research